Table 1 High expression of FLT3 was associated with a poor prognosis in AML, opposite to its role in solid cancers.
Dataset | Cancer type | Subtype | Endpoint | N | p-value | HR [95% CI] |
|---|---|---|---|---|---|---|
GSE12417-GPL96 | Blood cancer | AML | OS | 163 | 0.022265 | 1.26 [1.03–1.53] |
GSE11121 | Breast cancer | - | DMFS | 200 | 0.000397 | 0.46 [0.30–0.71] |
GSE19615 | Breast cancer | - | DMFS | 115 | 0.004782 | 0.22 [0.08–0.63] |
GSE1456-GPL96 | Breast cancer | - | OS | 159 | 0.034667 | 0.43 [0.20–0.94] |
GSE1456-GPL96 | Breast cancer | - | DSS | 159 | 0.037424 | 0.38 [0.15–0.94] |
GSE12276 | Breast cancer | - | RFS | 204 | 0.014298 | 0.85 [0.75–0.97] |
GSE17536 | Colorectal cancer | - | OS | 177 | 0.014674 | 0.18 [0.05–0.71] |
RGSE17536 | Colorectal cancer | - | DSS | 177 | 0.033747 | 0.18 [0.04–0.88] |
GSE19234 | Skin cancer | Melanoma | OS | 38 | 0.006952 | 0.36 [0.17–0.76] |
GSE22138 | Eye cancer | Uveal melanoma | DMFS | 63 | 0.039404 | 0.00 [0.00–0.31] |
